{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:07:20Z","timestamp":1791083240189,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"VA HSR&D Career Development Award","award":["11\u2013215"],"award-info":[{"award-number":["11\u2013215"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA BSI) usually receive initial treatment with vancomycin but may be switched to daptomycin for definitive therapy, especially if treatment failure is suspected. Our objective was to evaluate the effectiveness of switching from vancomycin to daptomycin compared with remaining on vancomycin among patients with MRSA BSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients admitted to 124 Veterans Affairs Hospitals who experienced MRSA BSI and were treated with vancomycin during 2007\u20132014 were included. The association between switching to daptomycin and 30-day mortality was assessed using Cox regression models. Separate models were created for switching to daptomycin any time during the first hospitalization and for switching within 3 days of receiving vancomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 7411 patients received vancomycin for MRSA BSI. Also, 606 (8.2%) patients switched from vancomycin to daptomycin during the first hospitalization, and 108 (1.5%) switched from vancomycin to daptomycin within 3 days of starting vancomycin. In the multivariable analysis, switching to daptomycin within 3 days was significantly associated with lower 30-day mortality (hazards ratio [HR] = 0.48; 95% confidence interval [CI]: .25, .92). However, switching to daptomycin at any time during the first hospitalization was not significantly associated with 30-day mortality (HR: 0.87; 95% CI: .69, 1.09).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to daptomycin within 3 days of initial receipt of vancomycin is associated with lower 30-day mortality among patients with MRSA BSI. This benefit was not seen when the switch occurred later. Future studies should prospectively assess the benefit of early switching from vancomycin to other anti-MRSA antibiotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1572","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T15:29:39Z","timestamp":1602602979000},"page":"S68-S73","source":"Crossref","is-referenced-by-count":41,"title":["Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant\n                    <i>Staphylococcus aureus<\/i>\n                    (MRSA) Bloodstream Infections"],"prefix":"10.1093","volume":"72","author":[{"given":"Marin L","family":"Schweizer","sequence":"first","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Richardson","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S","family":"Vaughan Sarrazin","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Goto","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Livorsi","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Nair","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice F","family":"Beck","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Jones","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Puig-Asensio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Suh","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Ohl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli N","family":"Perencevich","sequence":"additional","affiliation":[{"name":"Center for Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, Iowa USA"},{"name":"Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"2021012909150781900_CIT0001","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1080\/14656566.2017.1403585","article-title":"Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia","volume":"18","author":"Gudiol","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"2021012909150781900_CIT0002","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2147\/IDR.S159447","article-title":"Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections","volume":"11","author":"Shime","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2021012909150781900_CIT0003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2021012909150781900_CIT0004","author":"U.S. Food and Drug Administration"},{"key":"2021012909150781900_CIT0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC &gt;1 mg\/L: a multicenter evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin Ther"},{"key":"2021012909150781900_CIT0006","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"2021012909150781900_CIT0007","doi-asserted-by":"crossref","first-page":"ofy093","DOI":"10.1093\/ofid\/ofy093","article-title":"Management practices for methicillin-resistant Staphylococcus aureus bacteremia by adult infectious diseases physicians","volume":"5","author":"Banniettis","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021012909150781900_CIT0008","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciy774","article-title":"Considerations for clinical trials of Staphylococcus aureus bloodstream infection in adults","volume":"68","author":"Holland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021012909150781900_CIT0009","author":"Centers for Disease Control and Prevention"},{"key":"2021012909150781900_CIT0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jamainternmed.2017.3958","article-title":"Association of evidence-based care processes with mortality in Staphylococcus aureus bacteremia at Veterans Health Administration Hospitals, 2003\u20132014","volume":"177","author":"Goto","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2021012909150781900_CIT0011","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012909150781900_CIT0012","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021012909150781900_CIT0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1478-7954-4-2","article-title":"Accuracy and completeness of mortality data in the Department of Veterans Affairs","volume":"4","author":"Sohn","year":"2006","journal-title":"Popul Health Metr"},{"key":"2021012909150781900_CIT0014","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2021012909150781900_CIT0015","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.100.6.1619","article-title":"The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults","volume":"100","author":"Knaus","year":"1991","journal-title":"Chest"},{"key":"2021012909150781900_CIT0016","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcrc.2018.09.005","article-title":"An automated computerized critical illness severity scoring system derived from APACHE III: modified APACHE","volume":"48","author":"Fortis","year":"2018","journal-title":"J Crit Care"},{"key":"2021012909150781900_CIT0017","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1086\/653206","article-title":"Predictive ability of positive clinical culture results and International Classification of Diseases, Ninth Revision, to identify and classify noninvasive Staphylococcus aureus infections: a validation study","volume":"31","author":"Tracy","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012909150781900_CIT0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit Care"},{"key":"2021012909150781900_CIT0019","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021012909150781900_CIT0020","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021012909150781900_CIT0021","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/JCM.41.7.3163-3166.2003","article-title":"Comparison of culture screening methods for detection of nasal carriage of methicillin-resistant Staphylococcus aureus: a prospective study comparing 32 methods","volume":"41","author":"Safdar","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2021012909150781900_CIT0022","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13063-018-2702-8","article-title":"A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations\u2014results of a prematurely terminated study","volume":"19","author":"Kalimuddin","year":"2018","journal-title":"Trials"},{"key":"2021012909150781900_CIT0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.15585\/mmwr.mm6809e2","article-title":"Vital signs: trends in Staphylococcus aureus infections in veterans affairs medical centers\u2014United States, 2005\u20132017","volume":"68","author":"Jones","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021012909150781900_CIT0024","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021012909150781900_CIT0025","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1017\/ice.2017.83","article-title":"Attributable mortality of healthcare-associated infections due to multidrug-resistant gram-negative bacteria and methicillin-resistant Staphylococcus aureus","volume":"38","author":"Nelson","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012909150781900_CIT0026","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/phar.2070","article-title":"Association of higher daptomycin dose (7 mg\/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"38","author":"Timbrook","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2021012909150781900_CIT0027","first-page":"2112","article-title":"Methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States","volume":"69","author":"Inagaki","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/Supplement_1\/S68\/36141087\/ciaa1572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/Supplement_1\/S68\/36141087\/ciaa1572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:15:39Z","timestamp":1611893739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/Supplement_1\/S68\/6123348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":27,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,1,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1572","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,15]]},"published":{"date-parts":[[2021,1,15]]}}}